Session: Geldanamycin and Beyond: Progress Toward the Development of HSP90 Inhibitors


MEDI		Wednesday, 29 March 2006

8:30 AM-12:05 PM Georgia World Congress Center -- Georgia Ballroom 1, Oral
Geldanamycin and Beyond: Progress Toward the Development of HSP90 Inhibitors

Organizers:	Brian S. J. Blagg Robert A. Galemmo Jr.
8:30 AM		Introductory Remarks
8:35 AM	205	Is heat shock protein 90 the cancer chaperone? Len Neckers
9:10 AM	206	Design and development of purine-scaffold inhibitors of the heat shock protein 90 Gabriela Chiosis
9:45 AM	207	Rationally designed high-affinity 2-amino-6-halopurine Hsp90 inhibitors which exhibit potent antitumor activity Srinivas R. Kasibhatla, Kevin Hong, Marco A. Biamonte, David Bush, Patricia L. Karjian, John L Sensintaffar, Adeela Kamal, Rachel E. Lough, John Brekken, Karen Lundgren, Roy Grecko, Gregg A. Timony, Yingqing Ran, Robert Mansfield, Lawrence C. Fritz, Ed Ulm, Francis J. Burrows, Marcus F. Boehm
10:20 AM	208	Managing the Hsp90-mediated protein folding process with small molecules Brian S. J. Blagg
10:55 AM	209	Semisynthetic analogs of geldanamycin: Chemistry and biology David C. Myles
11:30 AM	210	Synthesis and biological evaluation of IPI-504, an aqueous soluble analog of 17-AAG and potent inhibitor of Hsp90 James R. Porter, Jie Ge, Emmanuel Normant, Janid Ali, Marlene S. Dembski, Yun Gao, Asimina T. Georges, Louis Grenier, Roger Pak, Jon Patterson, Jens R. Sydor, Jim Wright, Julian Adams, Jeffrey K. Tong